New release sharpens single-use: Sartorius Stedim Biotech’s Sartoflow Advance builds momentum

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/15/2026 at 8:19 PM ET. Details in the imprint.

Sartorius Stedim Biotech is expanding its single-use downstream portfolio with the Sartoflow Advance system, a modular tangential flow filtration platform designed for flexible mid-scale biologics and vaccine manufacturing. The system targets process development and clinical to commercial batches where manufacturers need to switch quickly between molecules while keeping footprints and changeover times low. According to the company, the unit supports both single-use and reusable configurations, giving process engineers more latitude when designing hybrid or fully disposable lines for modern biologics plants. The official Sartoflow Advance product page details its single-use and stainless-steel options.

Sartoflow Advance: what the new TFF platform is built to deliver

The Sartoflow Advance is positioned as a scalable tangential flow filtration (TFF) system for concentration and diafiltration steps, covering typical working volumes from roughly a few liters up to around 200 liters depending on cassette configuration and process design. Sartorius emphasizes that the skid is optimized for ultrafiltration and diafiltration of monoclonal antibodies, recombinant proteins and similar biologics, a segment where batch-to-batch flexibility and rapid changeovers have become critical as pipelines diversify. The platform supports Sartorius’ own cassette formats and membranes, which lets users standardize consumables across development and clinical manufacturing suites.

From an engineering standpoint, Sartoflow Advance is built with an integrated pump, control unit and instrumentation for parameters such as transmembrane pressure, retentate flow and conductivity, allowing automated control recipes for typical UF/DF workflows. The system is designed to operate with both single-use flow paths and conventional stainless-steel tubing, so sites that are still running legacy stainless infrastructure can introduce disposable assemblies step by step instead of replacing entire skids at once. This hybrid capability is aimed squarely at contract development and manufacturing organizations and mid-sized biopharma companies that want to expand capacity but are cautious about locking into one processing philosophy.

Automation is another focal point. The system interfaces with Sartorius control software and can be integrated into higher-level manufacturing execution and data environments, which helps standardize recipes and batch documentation across multiple units and sites. Pre-defined sequences for concentration and diafiltration runs can reduce operator variability, while data logging supports process analytical technology initiatives and regulatory filings. For facilities that already rely heavily on Sartorius sensors, filters and single-use assemblies, Sartoflow Advance fits into an ecosystem aimed at harmonizing hardware, consumables and automation from upstream through final formulation.

Regulatory and validation considerations are built into the design as well. Single-use flow paths are supplied with documentation packages to support qualification, and the control system is engineered to comply with typical pharmaceutical data integrity and audit trail expectations. By combining these digital features with process instrumentation tuned for biologics, Sartoflow Advance aims to shorten the time from lab-scale process definition to GMP-compliant manufacturing runs. In practice, that can mean fewer custom engineering projects for each new molecule and more reuse of standardized skids and recipes across different products.

Market demand is moving in the same direction. Analysts tracking tangential flow filtration equipment expect global TFF units to grow in the high single- to low double-digit percentage range annually over the next decade, driven by biologics capacity expansion, the shift to single-use processing and the need for modular systems that can be redeployed between sites as portfolios evolve. IndexBox, for example, sees TFF units as a beneficiary of broader biologics and single-use trends through 2035, highlighting the importance of flexible skids that can be tailored to new facilities and retrofits. A recent market outlook points to TFF unit demand rising with biologics and single-use adoption through 2035.

Within Sartorius Stedim Biotech’s broader portfolio, Sartoflow Advance fills a gap between smaller lab-scale units and fully customized process skids, reinforcing the company’s emphasis on single-use and hybrid solutions for biopharma manufacturing. The product complements Sartorius consumables such as cassettes, filters and single-use bags, which together account for a significant share of the group’s recurring revenue stream. Sartorius Stedim Biotech is part of the wider Sartorius group, which reports that equipment and consumables for biopharmaceutical production represent its core business by revenue. Sartorius’ investor relations material describes bioprocess solutions as its main revenue driver. Shares of Sartorius Stedim Biotech (FR0013154002) are listed on Euronext Paris; the most recent available quote showed the stock trading in euros on that venue.

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.